Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer
Prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer
(PCa) cells, and several PSMA ligands for PET imaging are now available worldwide. 68Ga …
(PCa) cells, and several PSMA ligands for PET imaging are now available worldwide. 68Ga …
Novel therapies are changing treatment paradigms in metastatic prostate cancer
Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with
an aggressive disease course despite currently approved therapeutics. The recent …
an aggressive disease course despite currently approved therapeutics. The recent …
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman… - European journal of …, 2023 - Springer
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer
Tumor expression of prostate-specific membrane antigen (PSMA) is lost in 15–20% of men
with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain …
with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …
prostate cancer have improved outcomes, but there are still many aspects of management …
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
V Bhatia, NV Kamat, TE Pariva, LT Wu, A Tsao… - Nature …, 2023 - nature.com
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for
therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 …
therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 …
Anti‐swelling, robust, and adhesive extracellular matrix‐mimicking hydrogel used as intraoral dressing
J Wu, Z Pan, ZY Zhao, MH Wang, L Dong… - Advanced …, 2022 - Wiley Online Library
Due to the wet and dynamic environment of the oral cavity, the healing of intraoral wounds,
such as tooth extraction wounds, requires stable and firm wound dressings. In clinical …
such as tooth extraction wounds, requires stable and firm wound dressings. In clinical …
Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic …
177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …